Anissa M. Cheung

FDA investigator · also recorded as Ue I. Anissa Cheung

Appears on 7 documents from 2017 to 2024, most often at sites in Massachusetts. Most often cites production record review (21 CFR 211.192).

7
Documents on file
7.0
Observations per 483
2017
First seen
2024
Most recent

What they cite most

From 35 observations

Activity by year

2017: 1, 2021: 3, 2023: 1, 2024: 2

Where

Massachusetts 2 · Belgium 1 · France 1 · India 1 · Japan 1 · United Kingdom 1

Is Anissa M. Cheung coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

7 documents, newest first
FirmOpen
483 SERUM INSTITUTE OF INDIA PRIVATE LIMITEDJul 2, 2024 · Pune, India
483 MedImmune UK LimitedMar 15, 2024 · Liverpool, United Kingdom
483 UNIGEN INC.Mar 9, 2023 · GIFU, Japan
483 Wyeth BioPharma Division of Wyeth Pharmaceuticals LLCJul 23, 2021 · Andover, Massachusetts
EIR Wyeth BioPharma Division of Wyeth Pharmaceuticals LLCJul 23, 2021 · Andover, Massachusetts
EIR Pfizer Manufacturing Belgium NVJul 2, 2021 · Puurs, Belgium
483 Sanofi Winthrop IndustrieSep 27, 2017 · Marcy L Etoile, France

About this profile

What does Anissa M. Cheung inspect?

Anissa M. Cheung appears on 7 documents on file covering 6 sites, most often in Massachusetts.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.42 and 21 CFR 211.100.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Anissa M. Cheung is dated Jul 2, 2024.